Trial Profile
Open Label Dose Escalation Trial of an Adaptive Natural Killer (NK) Cell Infusion (FATE-NK100) With Subcutaneous IL-2 in Adults With Refractory or Relapsed Acute Myelogenous Leukemia (AML)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs FATE NK100 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; First in man
- Acronyms VOYAGE
- 10 Mar 2021 Status changed from active, no longer recruiting to completed.
- 28 Feb 2020 Planned number of patients changed from 20 to 6.
- 28 Feb 2020 Status changed from recruiting to active, no longer recruiting.